Johnson & Johnson
Johnson & Johnson researches, develops, manufactures, and sells healthcare products worldwide. Its Innovative Medicine segment offers products for various therapeutic areas, including immunology, infectious diseases, oncology, cardiovascular, and more. The MedTech segment provides Interventional Solutions, including electrophysiology products and neurovascular care. It also offers orthopaedics, surgery portfolios, contact lenses, and intraocular lenses. Products are distributed to wholesalers, hospitals, retailers, physicians, nurses, and clinics.
Overview
Strengths
- Shows the financial signature of a durable competitive advantage (economic moat): consistently high returns on capital, returns well above its cost of capital, high, stable gross margins (pricing power) and operating margins that held up every year.
- Return on invested capital has stayed above 15% in each of the last 8 years (latest 18.9%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 18.9% against a cost of capital (WACC) of 5.8%, a spread of 13.2 percentage points.
- Pricing power: gross margin has held between 66% and 70% over the last 8 years (latest 67.9%).
- Scale advantage: ranks #2 by enterprise value ($684 billion) among the 28 Drug Manufacturers - General companies we cover.
- Shareholder-friendly capital allocation: the share count has shrunk by 2.7% a year over the last three years through buybacks.
Weaknesses
- Valued at a premium to its Drug Manufacturers - General peers: P/FCF 34.0x vs. a median of 20.8x and EV/EBITDA 19.5x vs. a median of 13.7x.
- More expensive than its own history: P/FCF 34.0x vs. a historical average of 21.1x.
Key Financial Data